◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › P › PGEN

Precigen Inc (PGEN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-31

Precigen Inc (PGEN) operates in the BIOTECHNOLOGY industry and is headquartered in Germantown, United States with about 160 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, PGEN reported $10M in revenue and ($251M) in net income.

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Interactive charts & full statements → Open the PGEN valuation workbench →

PGEN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$86M	$10M	$4M	$6M	$27M	$14M	$32M	$32M	$161M	$231M	$191M	$174M	$72M	$24M	$14M	$8M
Gross Profit	$77M	$4M	$0M	$0M	$21M	($39M)	($13M)	$27M	$97M	$168M	$129M	$110M	$53M	($24M)	($50M)	$8M
Gross Margin %	89.5%	37.0%	-8.7%	1.7%	76.4%	-276.2%	-40.0%	83.2%	60.6%	72.8%	67.7%	63.2%	73.2%	-102.7%	-359.9%	100.0%
Operating Income (EBIT)	($39M)	($107M)	($135M)	($100M)	($76M)	($92M)	($86M)	($86M)	($506M)	($138M)	($125M)	($147M)	($70M)	($58M)	($75M)	($82M)
Operating Margin %	-45.4%	-1100.8%	-3440.2%	-1602.5%	-281.4%	-644.5%	-269.8%	-269.8%	-314.9%	-59.7%	-65.6%	-84.6%	-97.3%	-244.2%	-539.7%	-1028.7%
Net Income	($158M)	($251M)	($126M)	($96M)	$28M	($92M)	($171M)	($171M)	($509M)	($117M)	($187M)	($84M)	($82M)	($39M)	($82M)	($85M)
Net Margin %	-183.7%	-2588.2%	-3216.2%	-1540.6%	105.2%	-646.0%	-533.0%	-533.0%	-317.2%	-50.7%	-97.7%	-48.7%	-113.8%	-164.1%	-588.0%	-1064.3%
EBITDA	($145M)	($244M)	($123M)	($89M)	($62M)	($78M)	($68M)	($69M)	($349M)	($98M)	($169M)	($68M)	($75M)	($34M)	($74M)	($81M)
Earnings Per Share (EPS)	$-0.55	$-0.82	$-0.47	$-0.39	$0.14	$-0.47	$-1.02	$-1.11	$-3.93	$-0.98	$-1.58	$-0.76	$-0.83	$-0.95	$-14.80	$-15.05
Shares Outstanding (M)	414M	305M	268M	245M	200M	198M	167M	154M	130M	120M	118M	111M	99M	—	6M	6M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PGEN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$55M	$23M	$5M	$3M	$1M	$1M	$1M	$1M
Gross Profit	$52M	$20M	$3M	$2M	($1M)	$0M	$0M	$0M
Gross Margin %	94.9%	87.6%	58.1%	53.7%	-81.7%	-5.8%	1.8%	-5.9%
Operating Income (EBIT)	$23M	($6M)	($22M)	($34M)	($32M)	($23M)	($29M)	($21M)
Operating Margin %	41.2%	-25.8%	-474.6%	-1180.0%	-3710.8%	-1685.0%	-2396.3%	-2231.1%
Net Income	$20M	($8M)	($24M)	($146M)	($27M)	($54M)	($20M)	($24M)
Net Margin %	36.5%	-34.1%	-514.9%	-5008.4%	-3112.4%	-4038.3%	-1657.7%	-2516.0%
EBITDA	$23M	($4M)	($19M)	($145M)	($27M)	($54M)	($19M)	($23M)
Earnings Per Share (EPS)	$0.05	$-0.03	$-0.08	$-0.49	$-0.09	$-0.18	$-0.07	$-0.09
Shares Outstanding (M)	414M	313M	313M	296M	296M	294M	293M	276M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PGEN Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($114M)	($88M)	($68M)	($67M)	($65M)	($56M)	($77M)	($77M)	($124M)	($104M)	($56M)	$36M	($20M)	($54M)	($62M)	($82M)
Capital Expenditures (CapEx)	$1M	$2M	$9M	$2M	$5M	$7M	$8M	$8M	$42M	$47M	$32M	$13M	$6M	$2M	$7M	$13M
Free Cash Flow (FCF)	($115M)	($90M)	($77M)	($68M)	($70M)	($63M)	($85M)	($85M)	($166M)	($151M)	($88M)	$23M	($26M)	($55M)	($69M)	($95M)
FCF Margin %	-133.7%	-927.6%	-1955.6%	-1099.9%	-260.0%	-441.7%	-264.3%	-264.3%	-103.3%	-65.3%	-45.9%	13.2%	-36.5%	-232.4%	-495.7%	-1182.6%
Dividends Paid	—	—	—	—	—	—	—	—	—	$8M	$42M	—	$7M	$151M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PGEN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($18M)	($44M)	($23M)	($29M)	($19M)	($16M)	($8M)	($23M)
Capital Expenditures (CapEx)	$0M	$0M	$1M	$0M	$1M	$1M	$1M	$1M
Free Cash Flow (FCF)	($18M)	($44M)	($24M)	($29M)	($20M)	($17M)	($9M)	($24M)
FCF Margin %	-33.1%	-189.6%	-527.5%	-1008.1%	-2329.8%	-1263.8%	-779.1%	-2478.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PGEN Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$170M	$157M	$145M	$151M	$216M	$360M	$315M	$456M	$716M	$847M	$949M	$982M	$576M	$469M	$152M	$115M
Cash & Cash Equivalents	$16M	$30M	$30M	$8M	$5M	$36M	$52M	$66M	$103M	$68M	$63M	$136M	$27M	$50M	$10M	$20M
Total Liabilities	$127M	$136M	$107M	$33M	$90M	$253M	$247M	$384M	$337M	$300M	$380M	$277M	$167M	$88M	$473M	$336M
Total Debt (Short + Long-Term)	$95M	$94M	$1M	$1M	$44M	$184M	$175M	$223M	$212M	$8M	$9M	$9M	$13M	$0M	$0M	$0M
Total Shareholders' Equity	$44M	$21M	$39M	$118M	$126M	$107M	$67M	$72M	$363M	$534M	$560M	$694M	$385M	$367M	($322M)	($221M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PGEN viewer.

Other Companies in BIOTECHNOLOGY

QURE · Uniqure NV — $3 billion
MBX · MBX Biosciences, Inc. Common Stock — $3 billion
CLDX · Celldex Therapeutics Inc — $3 billion
ZLAB · Zai Lab Ltd — $3 billion
ATAI · ATAI Life Sciences BV — $3 billion
IMNM · Immunome Inc — $3 billion
IRON · Disc Medicine Inc. — $3 billion
NRIX · Nurix Therapeutics Inc — $3 billion

← PGEL All “P” companies PGF →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.